Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma

By sjmartinez • July 12, 2023

Chehrazi-Raffle A, Leong S, Ali S, Kim T, Melamed S, Li X, Zengin Z, Meza L, Chawla N, Govindarajan A, Castro D, Mercier B, Ebrahimi H, Dizman N, Tripathi N, Sayegh N, Rock A, Yeh J, Pal SK, Onyshchenko M. Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma. Oncologist. 2023 Jul 11:oyad190. doi: 10.1093/oncolo/oyad190. Epub ahead of print. PMID: 37432304.

Tags: General Internal Medicine, Harbor UCLA, Hematology/Oncology, immune checkpoint inhibitors, immunotherapy, Latinx/Latino, Publications, real-world outcomes, renal-cell carcinoma, Social determinants of health

Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma

Lownik J, Boiarsky J, Birhiray R, Merchant A, Mead M. Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma. Clin Cancer Res.[...]

Outpatient hospitalist-run procedure service bridges the gap in oncology care

Ghanem G, Tsai HHC, Durant C, Feigenbaum GS, Glaeser AM. Outpatient hospitalist-run procedure service bridges the gap in oncology care. Transfus Apher Sci. 2024 Apr[...]

Statewide Survey of Primary Care and Subspecialty Providers on Hepatocellular Carcinoma Risk-Stratification and Surveillance Practices

Moon AM, Swier RM, Lane LM, Barritt AS 4th, Sanoff HK, Olshan AF, Wheeler SB, Ioannou GN, Kim NJ, Hagan S, Vutien P, Benefield T,[...]